Cartesian Therapeutics (RNAC) Asset Utilization Ratio (2016 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Asset Utilization Ratio data on file, last reported at 0.0 in Q1 2026.

• On a quarterly basis, Asset Utilization Ratio fell 95.59% year-over-year to 0.0 in Q1 2026; TTM through Mar 2026 was 0.0, a 95.59% decrease from a year earlier, with the FY2025 full-year figure at 0.01, down 92.61% from the prior year.
• Asset Utilization Ratio for Q1 2026 stood at 0.0, down from 0.01 in the prior quarter.
• Over the last five years, Asset Utilization Ratio for RNAC reached as high as 0.76 in Q2 2022 and fell as low as 0.0 in Q2 2025.
• Historically, Asset Utilization Ratio has averaged 0.27 across 5 years, with a median of 0.13 in 2023.
• Across the five-year window, Asset Utilization Ratio jumped 337.53% in 2022 and sank 99.59% in 2025, its largest moves.
• Year by year, Asset Utilization Ratio stood at 0.64 in 2022, then tumbled by 80.35% to 0.13 in 2023, then tumbled by 32.04% to 0.09 in 2024, then sank by 92.88% to 0.01 in 2025, then slumped by 42.71% to 0.0 in 2026.
• Per Business Quant data, the three most recent Asset Utilization Ratio figures were 0.0 in Q1 2026, 0.01 in Q4 2025, and 0.0 in Q3 2025.